10 series
Export
<<<Page of 1 >>>Page size
Accession Title Series type(s) Organism(s) Samples GDS Supplementary Contact Release date
Remove filtersFilter Remove filterBROADPEAK Remove filterXiaoping Su
GSE227024
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1 [ChIP-Seq]
6 Xiaoping Su Jun 14, 2023
GSE227025
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
10 Xiaoping Su Jun 14, 2023
GSE228323
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. [ChIP-Seq]
4
  • Download icon BROADPEAK
Xiaoping Su Apr 19, 2023
GSE228326
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
38 Xiaoping Su Apr 19, 2023
GSE247093
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression [ChIP-Seq]
12
  • Download icon BROADPEAK
Xiaoping Su May 06, 2024
GSE247095
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
28 Xiaoping Su May 06, 2024
GSE252739
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). [ChIP-Seq]
2
  • Download icon BROADPEAK
Xiaoping Su Feb 01, 2024
GSE252746
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
35 Xiaoping Su Feb 01, 2024
GSE252935
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (ChIP-Seq)
12 Xiaoping Su Mar 01, 2024
GSE252938
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor
34 Xiaoping Su Mar 01, 2024